scholarly journals Mass Antibody Detection: Can It be An Avenger for Infectivity War against COVID-19

2020 ◽  
Author(s):  
Sarfaraz Ahmad Ejazi ◽  
Sneha Ghosh ◽  
Nahid Ali
Keyword(s):  
Large Scale ◽  
Point Of Care ◽  
Cost Effective ◽  
Antibody Detection ◽  
Serological Tests ◽  
Ongoing Research ◽  
Molecular Tests ◽  
Immunological Assays ◽  
Commercial Kits ◽  
Vaccination Therapy

The ongoing pandemic of COVID-19 has not only commenced a global health emergency but agitated various aspects of humanity. During this period of crisis researchers over the world have ramped their efforts to constrain the disease in all possible ways whether it is vaccination, therapy, or diagnosis. Since the spread of the disease has not yet elapsed sharing the ongoing research findings could be the key to disease control and management. An early and efficient diagnosis could leverage the outcome until a successful vaccine is developed. Molecular tests both in-house and commercial kits are preferably being used worldwide in the COVID-19 diagnosis. However, the limitation of high prices and lengthy procedures impede their use for mass testing. Keeping the constant rise of infection in mind search for an alternative test that should be cost-effective, simple, and suitable for large scale testing and surveillance is a need of an hour. One such alternative could be the immunological tests. Therefore, in the last few months deluge of immunological rapid tests has been developed and validated across the globe. The objective of the present review is to share the diagnostic performance of various immunological assays reported so far in SARS-CoV-2 case detection. The article consolidated the studies (published and preprints) related to the serological tests such as chemiluminescence, enzyme-linked and lateral flow-based point-of-care tests in COVID-19 diagnosis and updated the current scenario. This review will hopefully be an add-on in COVID-19 research and will contribute to congregate the evidence for decision-making.

scholarly journals Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections

2021 ◽  
Vol 9 ◽  
Author(s):  
Dhanasekaran Sakthivel ◽  
David Delgado-Diaz ◽  
Laura McArthur ◽  
William Hopper ◽  
Jack S. Richards ◽  
...  
Keyword(s):  
Large Scale ◽  
Clinical Symptoms ◽  
Point Of Care ◽  
Cost Effective ◽  
Nucleic Acid Amplification ◽  
Diagnostic Tools ◽  
Rt Pcr ◽  
Serological Tests ◽  
Polymerase Chain ◽  
Effective Public Health

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a recently emerged and highly contagious virus that causes coronavirus disease 2019 (COVID-19). As of August 24, 2021, there were more than 212 million confirmed COVID-19 cases and nearly 4.4 million deaths reported globally. Early diagnosis and isolation of infected individuals remains one of the most effective public health interventions to control SARS-CoV-2 spread and for effective clinical management of COVID-19 cases. Currently, SARS-CoV-2 infection is diagnosed presumptively based on clinical symptoms and confirmed by detecting the viral RNA in respiratory samples using reverse transcription polymerase chain reaction (RT-PCR). Standard RT-PCR protocols are time consuming, expensive, and technically demanding, which makes them a poor choice for large scale and point-of-care screening in resource-poor settings. Recently developed isothermal nucleic acid amplification tests (iNAAT), antigen and/or serological tests are cost-effective to scale COVID-19 testing at the point-of-care (PoC) and for surveillance activities. This review discusses the development of rapid PoC molecular tools for the detection and surveillance of SARS-CoV-2 infections.

scholarly journals Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status

2021 ◽  
Author(s):  
Dr. Sally A Mahmoud ◽  
Subhashini Ganesan ◽  
shivaraj Naik ◽  
Safaa Bissar ◽  
Isra Al zamil ◽  
...  
Keyword(s):  
Large Scale ◽  
Neutralization Test ◽  
Cost Effective ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serological Tests ◽  
Post Vaccination ◽  
Parallel Testing ◽  
Test Kit ◽  
Commercial Market ◽  
Immunological Assays

Background The anti SARS CoV 2 immunological assays have promising applications in the control and surveillance of the current COVID 19 pandemic. Therefore, large number of serological assays are developed in the commercial market to measure SARS CoV 2 antibodies, which requires evaluation before their application in large scale. Objectives To evaluate the performances of commercially available serological assays for detecting SARS CoV 2 antibodies. Methods The study compared the performances of six different methods for detection of antibodies against SARS CoV 2 which includes (i) Genscript SARS CoV 2 surrogate virus neutralization test kit [Test A] (ii) Diasorin SARS CoV 2 S1 S2 IgG detection [Test B] (iii) Alinity SARS CoV 2 IgG II [Test C] (iv) Diasorin SARS CoV 2 TrimericS IgG [Test D] (v) Roche Elecsys Anti SARS CoV 2 cobas [Test E] (vi) AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F] against the gold standard Plaque Reduction Neutralization Test (PRNT). Results Test E had the highest sensitivity and Test A had the highest specificity The ROC for tests A, C, D and E showed optimum cutoffs that differed from the manufacturers recommendation. Test D had the best performance considering all the performance indicators with the highest agreement with the PRNT results. Parallel testing of test A with test D and test B had the optimum performance. Conclusion Serological assays that are commercially available are very promising and show good agreement with the standard PRNT results. Studies on large samples for optimization of the assay cutoff values and cost effective evaluations on parallel testing methods are needed to make recommendations on these commercial assays.

scholarly journals Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies in COVID-19 confirmed healthcare workers

2020 ◽  
Author(s):  
Danielle Dias Conte ◽  
Joseane Mayara Almeida Carvalho ◽  
Luciano Kleber de Souza Luna ◽  
Klinger Soares Faíco-Filho ◽  
Ana Helena Perosa ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Large Scale ◽  
Point Of Care ◽  
Antibody Test ◽  
Cost Effective ◽  
Lateral Flow ◽  
Rt Pcr ◽  
Serum Samples ◽  
Igg Antibody ◽  
Serological Tests

AbstractSince the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days post symptoms (DPS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum samples. Bioclin was more sensitive (p<0.01), regardless of the DPS. Thus, the Bioclin can be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.

scholarly journals Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

2020 ◽  
Author(s):  
Joachim Marien ◽  
Johan Michiels ◽  
Leo Heyndrickx ◽  
Karen Kerkhof ◽  
Nikki Foque ◽  
...  
Keyword(s):  
Large Scale ◽  
Detection Threshold ◽  
Neutralizing Antibody ◽  
Cost Effective ◽  
Antibody Detection ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Serological Tests ◽  
Specific Igg ◽  
Antibody Levels

Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and inexpensive. Current assays are either labour-intensive and require specialised facilities (e.g. virus neutralization assays), or expensive with suboptimal specificity (e.g. commercial ELISAs). Bead-based assays offer a cost-effective alternative and allow for multiplexing to test for antibodies of other pathogens. Here, we compare the performance of four antigens for the detection of SARS-CoV-2 specific IgG antibodies in a panel of sera that includes both severe (n=40) and mild (n=52) cases, using a neutralization and a Luminex bead-based assay. While we show that neutralising antibody levels are significantly lower in mild than in severe cases, we demonstrate that a combination of recombinant nucleocapsid protein (NP), receptor-binding domain (RBD) and the whole spike protein (S1S2) results in a highly sensitive (96%) and specific (99%) bead-based assay that can detect IgG antibodies in both groups. Although S1-specific IgG levels correlate most strongly with neutralizing antibody levels, they fall below the detection threshold in 10% of the cases in our Luminex assay. In conclusion, our data supports the use of RBD, NP and S1S2 for the development of SARS-CoV-2 serological bead-based assays. Finally, we argue that low antibody levels in mild/asymptomatic cases might complicate the epidemiological assessment of large-scale surveillance studies.

scholarly journals Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients

2020 ◽  
Author(s):  
E Tuaillon ◽  
K Bolloré ◽  
A Pisoni ◽  
S Debiesse ◽  
C Renault ◽  
...  
Keyword(s):  
Point Of Care ◽  
Marked Point ◽  
Humoral Response ◽  
Hospitalized Patients ◽  
Antibody Detection ◽  
Serological Tests ◽  
Molecular Tests ◽  
Antibody Assays ◽  
Point Of Care Tests ◽  
Kinetics Of

AbstractSARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests.In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA.Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon).The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.

scholarly journals Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1352
Author(s):  
Darius Riziki Martin ◽  
Nicole Remaliah Sibuyi ◽  
Phumuzile Dube ◽  
Adewale Oluwaseun Fadaka ◽  
Ruben Cloete ◽  
...  
Keyword(s):  
Low Income ◽  
Point Of Care ◽  
Health Care Systems ◽  
Cost Effective ◽  
Rapid Screening ◽  
Low Income Countries ◽  
Sputum Smear ◽  
Diagnostic Systems ◽  
Molecular Tests ◽  
Rapid Tests

The transmission of Tuberculosis (TB) is very rapid and the burden it places on health care systems is felt globally. The effective management and prevention of this disease requires that it is detected early. Current TB diagnostic approaches, such as the culture, sputum smear, skin tuberculin, and molecular tests are time-consuming, and some are unaffordable for low-income countries. Rapid tests for disease biomarker detection are mostly based on immunological assays that use antibodies which are costly to produce, have low sensitivity and stability. Aptamers can replace antibodies in these diagnostic tests for the development of new rapid tests that are more cost effective; more stable at high temperatures and therefore have a better shelf life; do not have batch-to-batch variations, and thus more consistently bind to a specific target with similar or higher specificity and selectivity and are therefore more reliable. Advancements in TB research, in particular the application of proteomics to identify TB specific biomarkers, led to the identification of a number of biomarker proteins, that can be used to develop aptamer-based diagnostic assays able to screen individuals at the point-of-care (POC) more efficiently in resource-limited settings.

scholarly journals Diagnosis of tuberculosis in wildlife: a systematic review

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Jobin Thomas ◽  
Ana Balseiro ◽  
Christian Gortázar ◽  
María A. Risalde
Keyword(s):  
Systematic Review ◽  
Test Performance ◽  
Diagnostic Tests ◽  
Large Scale ◽  
Diagnostic Techniques ◽  
Review Literature ◽  
Meat Industry ◽  
Post Mortem ◽  
Serological Tests ◽  
Ongoing Research

AbstractAnimal tuberculosis (TB) is a multi-host disease caused by members of the Mycobacterium tuberculosis complex (MTC). Due to its impact on economy, sanitary standards of milk and meat industry, public health and conservation, TB control is an actively ongoing research subject. Several wildlife species are involved in the maintenance and transmission of TB, so that new approaches to wildlife TB diagnosis have gained relevance in recent years. Diagnosis is a paramount step for screening, epidemiological investigation, as well as for ensuring the success of control strategies such as vaccination trials. This is the first review that systematically addresses data available for the diagnosis of TB in wildlife following the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The article also gives an overview of the factors related to host, environment, sampling, and diagnostic techniques which can affect test performance. After three screenings, 124 articles were considered for systematic review. Literature indicates that post-mortem examination and culture are useful methods for disease surveillance, but immunological diagnostic tests based on cellular and humoral immune response detection are gaining importance in wildlife TB diagnosis. Among them, serological tests are especially useful in wildlife because they are relatively inexpensive and easy to perform, facilitate large-scale surveillance and can be used both ante- and post-mortem. Currently available studies assessed test performance mostly in cervids, European badgers, wild suids and wild bovids. Research to improve diagnostic tests for wildlife TB diagnosis is still needed in order to reach accurate, rapid and cost-effective diagnostic techniques adequate to a broad range of target species and consistent over space and time to allow proper disease monitoring.

scholarly journals Performance of SARS-CoV-2 Serology tests: Are they good enough?

2020 ◽  
Author(s):  
Isabelle Piec ◽  
Emma English ◽  
M Annette Thomas ◽  
Samir Dervisevic ◽  
William D Fraser ◽  
...  
Keyword(s):  
Sensitivity And Specificity ◽  
Respiratory Infections ◽  
Point Of Care ◽  
False Negative ◽  
Rapid Test ◽  
Diagnostic Sensitivity ◽  
Medical Community ◽  
Antibody Detection ◽  
Serological Tests ◽  
Negative Results

AbstractBackgroundIn the emergency of the SARS-CoV-2 pandemic, great efforts were made to quickly provide serology testing to the medical community however, these methods have been introduced into clinical practice without the complete validation usually required by the regulatory organizations.MethodsSARS-CoV-2 patient samples (n=43) were analysed alongside pre-pandemic control specimen (n=50), confirmed respiratory infections (n=50), inflammatory polyarthritis (n=22) and positive for thyroid stimulating immunoglobulin (n=30). Imprecision, diagnostic sensitivity and specificity and concordance were evaluated on IgG serologic assays from EuroImmun, Epitope Diagnostics (EDI), Abbott Diagnostics and DiaSorin and a rapid IgG/IgM test from Healgen.ResultsEDI and EuroImmun imprecision was 0.02-14.0% CV. Abbott and DiaSorin imprecision (CV) ranged from 5.2% - 8.1% and 8.2% - 9.6% respectively. Diagnostic sensitivity of the assays were 100% (CI: 80-100%) for Abbott, EDI and EuroImmun and 95% (CI: 73-100%) for DiaSorin at ≥14 days post PCR. Only the Abbott assay had a diagnostic specificity of 100% (CI: 91-100%). EuroImmun cross-reacted in 3 non-SARS-CoV-2 respiratory infections and 2 controls. The DiaSorin displayed more false negative results and cross-reacted in six cases across all conditions tested. EDI had one cross-reactive sample. The Healgen rapid test showed excellent sensitivity and specificity. Overall, concordance of the assays ranged from 76.1% to 97.9%.ConclusionsSerological tests for SARS-CoV-2 showed good analytical performance. The head-to-head analysis of samples revealed differences in results that may be linked to the use of nucleocapsid or spike proteins. The point of care device tested demonstrated adequate performance for antibody detection.

scholarly journals Evaluation of Large-Scale Rapid Antigen Testing of Incoming Passengers at a Dynamic Point of Care Setting Carried Out by Dental Students for Covid-19 Screening – A Field Report

2021 ◽  
Vol 10 (33) ◽  
pp. 2734-2739
Author(s):  
Akshay K. Langalia ◽  
Dolly P. Patel ◽  
Aravind D. Kumbhar ◽  
Hetal J. Maheshwari ◽  
Shubhangi K. Vyas ◽  
...  
Keyword(s):  
Large Scale ◽  
Point Of Care ◽  
Dental Students ◽  
Antigen Detection ◽  
Rapid Antigen Detection Test ◽  
Molecular Tests ◽  
Testing Facility ◽  
Field Report ◽  
Antigen Testing ◽  
Central Station

BACKGROUND Assessment of the results of large-scale rapid antigen diagnostic (RAD) testing for detection of SARS-CoV-2 amongst incoming passengers was carried out by Ahmedabad Municipal Corporation (AMC) Dental College Students at the Central Railway Station of Ahmedabad city. We wanted to determine the sensitivity and specificity of RAD testing for detection of Covid-19 amongst passengers disembarking from scheduled trains arriving at the Central Railway Terminus of Ahmedabad city. METHODS Under the campaign “Chase the Virus” launched by Ahmedabad Municipal Corporation (AMC), Interns & Final Year students of AMC Dental College were trained to carry out rapid antigen testing of scheduled trains running on special routes starting from 07 / 09 / 2020 to 05 / 10 / 2020. 14 dental teams were deputed at a temporary testing facility formulated for day-to-day testing at the Central Station using the standalone Standard - Q Covid-19 Ag testing kit (SD Biosensor, South Korea). RESULTS In total, 18901 travellers were tested in a span of 26 days out of which 324 tested positive with an overall percentage positivity of 1.71 %. An average number of 727 (± 182) tests were performed with an overall sensitivity of 66.01 % and specificity of 99.71 %. CONCLUSIONS In response to the growing Covid-19 pandemic and complexity of laboratory-based molecular tests, rapid antigen detection tests have proved to be efficient in the easier and faster diagnosis of the passengers in such point of care settings. KEY WORDS Rapid Antigen Detection Test, Covid-19, SARS-CoV-2

scholarly journals Development of a Diagnostic Biosensor Method of Hypersensitivity Pneumonitis towards a Point-of-Care Biosensor

Biosensors ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 196
Author(s):  
Tatiana Fiordelisio ◽  
Ivette Buendia-Roldan ◽  
Mathieu Hautefeuille ◽  
Diana Del-Rio ◽  
Diana G. Ríos-López ◽  
...  
Keyword(s):  
Hypersensitivity Pneumonitis ◽  
Magnetic Beads ◽  
Point Of Care ◽  
Cost Effective ◽  
High Volume ◽  
Antibody Detection ◽  
Optical Detectors ◽  
Conventional Elisa ◽  
Increasing Trend ◽  
A Current

In spite of a current increasing trend in the development of miniaturized, standalone point-of-care (PoC) biosensing platforms in the literature, the actual implementation of such systems in the field is far from being a reality although deeply needed. In the particular case of the population screenings for local or regional diseases related to specific pathogens, the diagnosis of the presence of specific antibodies could drastically modify therapies and even the organization of public policies. The aim of this work was to develop a fast, cost-effective detection method based on the manipulation of functionalized magnetic beads for an efficient diagnosis of hypersensitivity pneumonitis (HP), looking for the presence of anti-pigeon antigen antibodies (APAA) in a patient’s serum. We presented a Diagnostic Biosensor Method (DBM) in detail, with validation by comparison with a traditional high-throughput platform (ELISA assay). We also demonstrated that it was compatible with a microfluidic chip that could be eventually incorporated into a PoC for easy and broad deployment using portable optical detectors. After standardization of the different reaction steps, we constructed and validated a plastic chip that could easily be scaled to high-volume manufacturing in the future. The solution proved comparable to conventional ELISA assays traditionally performed by the clinicians in their laboratory and should be compatible with other antibody detection directly from patient samples.

Sign in / Sign up

Export Citation Format

Share Document